Provider Insights on the Impact of 340B Pricing

TKG PACT Executive Briefings - 3-Minute Market Insights

Content provided by The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Kinetix Group, Powered by Petauri, The Kinetix Group, and Powered by Petauri or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

2M ago 3:54

MP3•Episode home

Send us a text

Provider Insights on the Impact of 340B Pricing.

We frequently get asked for insights on how the 340B Drug Pricing Program may... or may not... be impacting the prescribing choices of participating covered entities. The Health Resources and Services Administration (HRSA) administers this federal program which is intended to help safety-net providers carry out their missions to serve their communities.

The Kinetix Group (TKG) recently conducted a market access research study to gain insights from healthcare providers on how the 340B program is impacting care delivery in covered entities. You can reach out to us for the full study, but a few of the highlights from our study are included in this briefing

You can download the full Executive Briefing at: https://tkgpact.com/executive-briefings/

Or, feel free to email us at Insights@thekinetixgroup.com

59 episodes

#Fitness #Medicine #The Kinetix Group #Healthcare #Pharma #Voice #Triple Aim #Biotech #Health Management #Science #Alternative Health #Biology #Insight